What I remember about our agreement for the Vyera was that it had performance clauses that allowed an easy out of our contract. The big items were 18 million dollars fee for the BLA to the FDA and $100 million in advertising and education of Doctors in the use of Leronlimab. If they do not perform to a certain level and timeline we can terminate our contract. It would appear with a new 22mm company in Regnum they might struggle to tow the line and would be easy to escape from a contract. Just my opinion…